This study is currently not recruiting participants.

A Phase II Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas

Investigating an Investigational Medication for Thymic Cancer

Not Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to learn if the study drug BKM120 can shrink pr slow the growth of thymic cancer.

Detailed description of study

The purpose of this study is to evaluate the objective response rate (CR+PR) in patients with thymomas treated with BKM120.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: thymomas
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the effects of an investigational medication on thymic cancer, a type of cancer that begins in the thymus gland. The purpose of this study is to determine if the investigational medication can shrink or slow the growth of thymic cancer.

Participants in the study will receive the investigational medication and will be monitored to evaluate the objective response rate, which refers to the measurement of tumor size reduction or stabilization. This study aims to assess how well the investigational medication works in treating patients with thymomas, a type of tumor in the thymus gland.

  • Who can participate: Participants must be adults diagnosed with thymic cancer. Key eligibility factors include measurable disease and adequate organ function.
  • Study details: Participants will receive the investigational medication and undergo regular monitoring to assess the response of their thymic cancer to the treatment.
Updated on 19 Feb 2024. Study ID: 1407518746 (IUCRO-0478)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team